摘要
肝细胞性肝癌(HCC)是来源于肝细胞的一种恶性肿瘤。欧洲肝脏研究学会指出,2014年全球HCC已经成为男性第五大恶性肿瘤,在女性恶性肿瘤中排名第八位,占全球癌症总数的5.4%。慢性乙型肝炎病毒(HBV)感染是临床上HCC的重要诱因。我国拥有全球最多的乙型肝炎患者,且80.0%~90.0%由慢性肝炎肝硬化发展而来,成为我国癌症死亡的主要原因。近年来,在HCC的治疗中出现乙型肝炎病毒再激活现象,容易造成患者肝功能衰竭,严重者甚至威胁患者生命。因此,加强药物干预预防原发性肝癌相关HBV再激活对改善患者预后具有重要的意义。目前,临床上常用的预防药物包括拉米夫定、恩替卡韦等,但对于药物安全性缺乏报道。本文以原发性肝癌相关HBV再激活为起点,分析拉米夫定、恩替卡韦在原发性肝癌相关HBV再激活中的应用效果及药物安全性。
Hepatocellular carcinoma （HCC） is a malignant tumor derived from hepatocyte. According to the European institute of liver research, the global incidence of HCC in 2014 has become the fifth largest malignancy in men, ranking the eighth in female malignant tu- mors, accounting for 5.4% of the total cancer patients worldwide. Chronic hepatitis B virus infection is the important inducer of clinical HCC. The China owns the most hepatitis B patients in the world, and 80.0% to 90.0% of patients were developed by chronic hepatitis and liver cirrhosis, so it has become China＇s leading cause of cancer deaths. In recent years, the occurrence of hepatitis B virus reactivation in HCC treatment can cause liver failure of patients and even life-threatening severely. Therefore, it is of great importance to strengthen drug inter- vention to prevent primary HBV reactivation and to improve the prognosis of patients. Currently, lamivudine and entecavir are two clinically common preventive drugs, but there is a lack of report on drug safety. This paper put the HBV reactivation in primary liver cancer as a start- ing point, analyzed the application effect and safety of lamivudine and entecavir for primary liver cancer related HBV reactivation.
出处
《肿瘤药学》
CAS
2017年第4期391-394,共4页
Anti-Tumor Pharmacy
基金
云南省医用基础研究计划青年项目(2014FD096)
关键词
肝细胞性肝癌
慢性乙型肝炎
药物干预
安全性
临床效果
Hepatocellular carcinoma
Chronic hepatitis B
Drug intervention
Safety
Clinical effect
